Balancing Bleeding Risk and Thromboembolic Complications in Elderly Chronic Subdural Hematoma Patients Undergoing Burr Hole Trephination : A Multicenter Retrospective Cohort Study and Literature Review
- PMID: 37551410
- PMCID: PMC10641412
- DOI: 10.3340/jkns.2023.0115
Balancing Bleeding Risk and Thromboembolic Complications in Elderly Chronic Subdural Hematoma Patients Undergoing Burr Hole Trephination : A Multicenter Retrospective Cohort Study and Literature Review
Abstract
Objective: Chronic subdural hematoma (CSDH) patients using antithrombotic agents (AT) at high risk for cardiovascular disease are increasing. The authors aimed to analyze the factors influencing outcome by targeting patients using AT and to establish a desirable treatment strategy.
Methods: A retrospective analysis was performed on data from 462 patients who underwent burr hole trephination (BHT) surgery for CSDH at five hospitals from March 2010 to June 2021. Outcomes included incidence of postoperative acute bleeding, recurrence rate, and morbidity or mortality rate. Patients were divided into the following four groups based on their history of AT use : no AT. Only antiplatelet agents (AP), only anticoagulants (AC), both of AP and AC. In addition, a concurrent literature review was conducted alongside our cohort study.
Results: Of 462 patients, 119 (119/462, 25.76%) were using AT. AP prescription did not significantly delay surgery (p=0.318), but AC prescription led to a significant increase in the time interval from admission to operation (p=0.048). After BHT, AP or AC intake significantly increased the period required for an in-dwelling drain (p=0.026 and p=0.037). The use of AC was significantly related to acute bleeding (p=0.044), while the use of AP was not (p=0.808). Use of AP or AC had no significant effect on CSDH recurrence (p=0.517 and p=1.000) or reoperation (p=0.924 and p=1.000). Morbidity was not statistically correlated with use of either AP or AC (p=0.795 and p=0.557, respectively), and there was no significant correlation with mortality for use of these medications (p=0.470 and p=1.000).
Conclusion: Elderly CSDH patients may benefit from maintenance of AT therapy during BHT due to reduced thromboembolic risk. However, the use of AC necessitates individualized due to potential postoperative bleeding. Careful post-operative monitoring could mitigate prognosis and recurrence impacts.
Keywords: Antithrombotic agent; Complications; Hematoma, subdural, chronic; Treatment outcome; Trephining.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
Similar articles
-
Subperiosteal versus Subdural Drain After Burr-hole Drainage Under Blood Thinners: A Subanalysis of the cSDH-Drain RCT.World Neurosurg. 2020 Jul;139:e113-e120. doi: 10.1016/j.wneu.2020.03.134. Epub 2020 Apr 2. World Neurosurg. 2020. PMID: 32247794 Clinical Trial.
-
Comparative analysis of safety and efficacy in subperiosteal versus subdural drainage after burr-hole trephination for chronic subdural hematoma.Clin Neurol Neurosurg. 2022 Jan;212:107068. doi: 10.1016/j.clineuro.2021.107068. Epub 2021 Nov 25. Clin Neurol Neurosurg. 2022. PMID: 34847484
-
Transition of a Clinical Practice to Use of Subdural Drains after Burr Hole Evacuation of Chronic Subdural Hematoma: The Helsinki Experience.World Neurosurg. 2019 Sep;129:e614-e626. doi: 10.1016/j.wneu.2019.05.230. Epub 2019 May 31. World Neurosurg. 2019. PMID: 31158547
-
Subperiosteal versus subdural drainage after burr hole evacuation of chronic subdural hematoma: systematic review and meta-analysis.Acta Neurochir (Wien). 2020 Mar;162(3):489-498. doi: 10.1007/s00701-019-04208-5. Epub 2020 Jan 15. Acta Neurochir (Wien). 2020. PMID: 31940094
-
Which surgical procedure is effective for refractory chronic subdural hematoma? Analysis of our surgical procedures and literature review.J Clin Neurosci. 2018 Mar;49:40-47. doi: 10.1016/j.jocn.2017.11.009. Epub 2017 Dec 20. J Clin Neurosci. 2018. PMID: 29274740 Review.
Cited by
-
Association between postoperative thromboembolic and hemorrhagic complications and clinical outcomes after surgery for chronic subdural hematoma in patients with anticoagulation therapy for atrial fibrillation.Acta Neurochir (Wien). 2025 Jan 16;167(1):17. doi: 10.1007/s00701-024-06417-z. Acta Neurochir (Wien). 2025. PMID: 39815109 Free PMC article. Clinical Trial.
-
Therapeutic efficacy of drilling drainage combined with intraoperative middle meningeal artery occlusion in the management of chronic subdural hematoma: a clinical study.Neurosurg Rev. 2024 Jun 25;47(1):293. doi: 10.1007/s10143-024-02501-1. Neurosurg Rev. 2024. PMID: 38914867 Free PMC article. Clinical Trial.
-
Evaluation of clinical outcome and predictive factors for thromboembolism or hemorrhagic complications in patients treated for chronic subdural hematoma. A prospective observational study.Neurosurg Rev. 2025 Mar 17;48(1):305. doi: 10.1007/s10143-025-03441-0. Neurosurg Rev. 2025. PMID: 40095196 Free PMC article.
-
Editors' Pick in November 2023.J Korean Neurosurg Soc. 2023 Nov;66(6):609-610. doi: 10.3340/jkns.2023.0218. Epub 2023 Nov 1. J Korean Neurosurg Soc. 2023. PMID: 37952535 Free PMC article. No abstract available.
References
-
- Abboud T, Dührsen L, Gibbert C, Westphal M, Martens T. Influence of antithrombotic agents on recurrence rate and clinical outcome in patients operated for chronic subdural hematoma. Neurocirugia (Astur : Engl Ed) 2018;29:86–92. - PubMed
-
- Amano T, Takahara K, Maehara N, Shimogawa T, Mukae N, Sayama T, et al. Optimal perioperative management of antithrombotic agents in patients with chronic subdural hematoma. Clin Neurol Neurosurg. 2016;151:43–50. - PubMed
-
- Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140:e596–e646. - PMC - PubMed
LinkOut - more resources
Full Text Sources